Evaluation of hepatic fibrosis in HIV/HCV co-infected individuals in Yaoundé, Cameroon: usefulness of APRI score in resource-constrained settings.
Rodolphe DobseuAubin Joseph NanfackMathurin KowoGeorgia AmbadaRachel KamgaingCollins ChenwiNadine FainguemAude Ka'eEric NgangoumSamuel SossoClergé TchiegangAlexis NdjoloPublished in: BMC infectious diseases (2020)
A high level of AST combined with thrombocytopenia (APRI score > 1.5) is an indicator of hepatic fibrosis in HIV/HCV co-infected individuals. Because of its non-invasive and less costly nature, the APRI score can be a suitable biomarker to monitor hepatic fibrosis in HIV/HCV co-infected individuals in resource constrained settings.